Allopurinol is the most frequent cause of Stevens–Johnson syndrome and toxic epidermal necrolysis

References

• Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens–Johnson syndrome, and erythema multiforme. Arch. Dermatol. 129(1), 92–96 (1993).
   PubMed Web of Science ®Google Scholar
• Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC; SCAR Study Group. Severe Cutaneous Adverse Reactions. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens–Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch. Dermatol. 138(8), 1019–1024 (2002).
   PubMed Web of Science ®Google Scholar
• Mockenhaupt M. The current understanding of Stevens–Johnson syndrome and toxic epidermal necrolysis. Expert. Rev. Clin. Immunol. 7(6), 803–815 (2011).
   PubMed Web of Science ®Google Scholar
• Rzany B, Mockenhaupt M, Baur S et al. Epidemiology of erythema exsudativum multiforme majus, Stevens–Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): structure and results of a population-based registry. J. Clin. Epidemiol. 49(7), 769–773 (1996).
   PubMed Web of Science ®Google Scholar
• Mockenhaupt M. Severe cutaneous adverse reactions. In: Braun-Falco’s Dermatology (3rd Edition). Burgdorf WHC, Plewig G, Wolff HH, Landthaler M (Eds). Springer Medizin Verlag, Heidelberg, Germany, 473–483 (2008).
   Google Scholar
• Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med. 333(24), 1600–1607 (1995).
   PubMed Web of Science ®Google Scholar
• Mockenhaupt M, Viboud C, Dunant A et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J. Invest. Dermatol. 128(1), 35–44 (2008).
   PubMed Web of Science ®Google Scholar
• Halevy S, Ghislain PD, Mockenhaupt M et al.; EuroSCAR Study Group. Allopurinol is the most common cause of Stevens–Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J. Am. Acad. Dermatol. 58(1), 25–32 (2008).
   PubMed Web of Science ®Google Scholar
• Smith P, Karlson N, Nair BR. Quality use of allopurinol in the elderly. J. Qual. Clin. Pract. 20(1), 42–43 (2000).
   PubMedGoogle Scholar
• Devlin JW, Bellamy N, Bayliff CD. Observations and effects of educational consults on allopurinol prescribing. Can. J. Hosp. Pharm. 45(1), 21–27 (1992).
   PubMedGoogle Scholar
• Agence Française de Securité Sanitaire des Produits de Santé. Analyse de Ventes de Médicaments aux Officines et aux Hôpitaux en France: 1991–2001 (3ème édition). AFSSAPS, Saint Denis, France (2003).
   Google Scholar
• Schwabe U, Paffrath D (Eds.) Arzneimittelverordnungs-Report 2008. Springer Medizin Verlag, Heidelberg, Germany (2008).
   Google Scholar
• Khoo BP, Leow YH. A review of inpatients with adverse drug reactions to allopurinol. Singapore Med. J. 41(4), 156–160 (2000).
   PubMedGoogle Scholar
• Hung SI, Chung WH, Liou LB et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102(11), 4134–4139 (2005).
   PubMed Web of Science ®Google Scholar
• Lonjou C, Borot N, Sekula P et al.; RegiSCAR study group. A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomics 18(2), 99–107 (2008).
   PubMed Web of Science ®Google Scholar
• Pichler WJ, Naisbitt DJ, Park BK. Immune pathomechanism of drug hypersensitivity reactions. J. Allergy Clin. Immunol. 127(Suppl. 3), S74–S81 (2011).
   PubMed Web of Science ®Google Scholar
• Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J. Allergy Clin. Immunol. 127(Suppl. 3), S60–S66 (2011).
   PubMed Web of Science ®Google Scholar
• Dincer HE, Dincer AP, Levinson DJ. Asymptomatic hyperuricemia: to treat or not to treat. Cleve. Clin. J. Med. 69(8), 594, 597, 600–602 (2002).
   PubMed Web of Science ®Google Scholar